<DOC>
	<DOCNO>NCT00002446</DOCNO>
	<brief_summary>The purpose study compare safety effectiveness 2 treatment thrush ( fungal infection mouth throat ) HIV-positive patient . Fluconazole drug commonly use treat thrush . SCH 56592 new drug compare fluconazole .</brief_summary>
	<brief_title>Safety Effectiveness Fluconazole Versus SCH 56592 Treat Thrush HIV-Positive Patients</brief_title>
	<detailed_description>Patients receive SCH 56592 oral suspension fluconazole suspension 14 day . Patients remain study 44 day total monitor safety efficacy study treatment .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis , Oral</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Posaconazole</mesh_term>
	<criteria>Inclusion Criteria You may eligible study : Are least 18 year old . Are HIVpositive . Have thrush ( oropharyngeal candidiasis ) . Agree practice sexual abstinence use effective barrier method birth control ( e.g. , condom ) . Are able take study medication return clinic visit study . Are expected live least 2 month . Exclusion Criteria You eligible study : Have receive protease inhibitor first time within 30 day prior study entry . Have receive certain medication . Have certain type fungal infection . Have certain type cancer . Have receive SCH 56592 within 3 month prior study entry . Are pregnant breastfeeding . Can take medication mouth . Are allergic azole drug . Have certain medical condition . Have study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2000</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Fluconazole</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>Antifungal Agents</keyword>
	<keyword>Candidiasis , Oral</keyword>
	<keyword>Pharyngeal Diseases</keyword>
	<keyword>posaconazole</keyword>
</DOC>